Listed

Innate Pharma SA: Form 20-F for the period ended Dec 31, 2024

Filed with the SEC on Apr 30, 2025 and accepted by EDGAR at Apr 30, 2025, 09:01 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2024-01-01 to 2024-12-31EUR 20.1mifrs-full:Revenue
Operating income12 months2024-01-01 to 2024-12-31−EUR 51.6mifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2024-01-01 to 2024-12-31EUR 0ifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2024-01-01 to 2024-12-31−EUR 49.5mifrs-full:ProfitLoss
Diluted EPS12 months2024-01-01 to 2024-12-31−EUR 0.61ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2024-01-01 to 2024-12-31−EUR 0.61ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2024-01-01 to 2024-12-31−EUR 6.9mifrs-full:CashFlowsFromUsedInOperatingActivities
Capital expenditure12 months2024-01-01 to 2024-12-31EUR 391.0kifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
Cash and equivalentsAt period end2024-12-31EUR 66.4mifrs-full:CashAndCashEquivalents
Current assetsAt period end2024-12-31EUR 85.7mifrs-full:CurrentAssets
Total assetsAt period end2024-12-31EUR 111.1mifrs-full:Assets
Current liabilitiesAt period end2024-12-31EUR 33.0mifrs-full:CurrentLiabilities
Shareholders' equityAt period end2024-12-31EUR 8.8mifrs-full:Equity
Shares outstandingAt period end2024-12-3183,830,336 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001598599-25-000042. Last ingested by Listed: Nov 12, 2026, 17:11 ET. Listed shows no prices and gives no investment advice.